MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

Search

10X Genomics Inc (Class A)

Geschlossen

BrancheGesundheitswesen

12.05 3.7

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

11.23

Max

12.4

Schlüsselkennzahlen

By Trading Economics

Einkommen

15M

-34M

Verkäufe

-10M

155M

EPS

-0.102

Gewinnspanne

-22.183

Angestellte

1,306

EBITDA

-1.5M

-39M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+12.96% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

7. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

366M

1.4B

Vorheriger Eröffnungskurs

8.35

Vorheriger Schlusskurs

12.05

Nachrichtenstimmung

By Acuity

34%

66%

93 / 380 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bullish Evidence

10X Genomics Inc (Class A) Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

1. Juli 2025, 23:09 UTC

Ergebnisse

Constellation Brands 1Q Profit, Sales Decline Amid Softer Consumer Demand -- Update

1. Juli 2025, 19:16 UTC

Akquisitionen, Fusionen, Übernahmen

Sabadell Seeks Shareholder Approval of Nearly $4 Billion Sale of U.K. Unit to Santander

1. Juli 2025, 23:47 UTC

Market Talk

Nikkei May Fall Amid U.S. Tariff Uncertainty -- Market Talk

1. Juli 2025, 23:41 UTC

Market Talk

Gold Steady, Underpinned by U.S. Fiscal-Deficit Concerns -- Market Talk

1. Juli 2025, 22:23 UTC

Akquisitionen, Fusionen, Übernahmen

James Hardie: Deal Represents Implied Value of $8.4 Billion

1. Juli 2025, 22:23 UTC

Akquisitionen, Fusionen, Übernahmen

James Hardie: Cash and Stock Deal Implies $54.18 Per AZEK Share

1. Juli 2025, 22:21 UTC

Akquisitionen, Fusionen, Übernahmen

James Hardie Completes Acquisition of AZEK

1. Juli 2025, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

1. Juli 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

1. Juli 2025, 20:24 UTC

Ergebnisse

Constellation Brands Earnings Miss as Consumers Cool on Alcohol -- Barrons.com

1. Juli 2025, 19:55 UTC

Market Talk

Oil Futures Resume Cautious Rally -- Market Talk

1. Juli 2025, 19:27 UTC

Market Talk

U.S. Natural Gas Futures Lose More Ground -- Market Talk

1. Juli 2025, 19:12 UTC

Market Talk

Dollar Little Changed as Tax-And-Spending Bill Advances -- Market Talk

1. Juli 2025, 19:01 UTC

Akquisitionen, Fusionen, Übernahmen

Sabadell Seeks Shareholder Approval of Nearly $4B Sale of U.K. Unit to Santander

1. Juli 2025, 18:41 UTC

Akquisitionen, Fusionen, Übernahmen

How DexCom, Insulet, and Amedisys Might Be Affected by Medicare Cuts -- Barrons.com

1. Juli 2025, 18:33 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

1. Juli 2025, 18:33 UTC

Market Talk

Gold Gains as Investors Look Ahead on Budget Bill -- Market Talk

1. Juli 2025, 18:32 UTC

Market Talk

Mexico Manufacturing PMIs Remain Weak in June -- Market Talk

1. Juli 2025, 18:22 UTC

Market Talk

Remittances to Mexico Down in May -- Market Talk

1. Juli 2025, 17:45 UTC

Market Talk

Seasonal Demand Supports Further Oil Gains -- Market Talk

1. Juli 2025, 17:01 UTC

Akquisitionen, Fusionen, Übernahmen

Danone Completed Acquisition of Majority Stake in Kate Farms

1. Juli 2025, 16:55 UTC

Ergebnisse

10 European Dividend Stocks That Could Beat Their U.S. Counterparts -- Barrons.com

1. Juli 2025, 16:27 UTC

Market Talk

Trade Concerns Ease in Bank of Mexico Survey -- Market Talk

1. Juli 2025, 16:25 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Home Depot's GMS Buy Unlocks New Vertical Adjacent to SRS -- Market Talk

1. Juli 2025, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

1. Juli 2025, 15:48 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Home Depot's Offer for GMS Unlikely to Be Beat -- Market Talk

1. Juli 2025, 15:46 UTC

Market Talk

Global Equities Roundup: Market Talk

1. Juli 2025, 15:46 UTC

Market Talk

Amazon Seen With Improved Logistics Ahead of Longer Prime Day -- Market Talk

1. Juli 2025, 14:54 UTC

Market Talk

Thales Expected to Stick to This Year's Sales Guidance -- Market Talk

1. Juli 2025, 14:49 UTC

Market Talk

Platinum Prices Extend Rally on China Demand, Supply Worries -- Market Talk

Peer-Vergleich

Kursveränderung

10X Genomics Inc (Class A) Prognose

Kursziel

By TipRanks

12.96% Vorteil

12-Monats-Prognose

Durchschnitt 13.25 USD  12.96%

Hoch 18 USD

Tief 9 USD

Basierend auf 10 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für 10X Genomics Inc (Class A) – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

10 ratings

4

Buy

6

Halten

0

Sell

Technischer Score

By Trading Central

8.32 / 8.63Unterstützung & Widerstand

Kurzfristig

Bullish Evidence

Mittelfristig

Bullish Evidence

Langfristig

No Evidence

Stimmung

By Acuity

93 / 380 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Durchschnitt

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über 10X Genomics Inc (Class A)

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.